| Literature DB >> 28624464 |
Elizabeth Harris1, Umar Burki1, Chiara Marini-Bettolo1, Marcella Neri2, Chiara Scotton2, Judith Hudson3, Marta Bertoli1, Teresinha Evangelista1, Bas Vroling4, Tuomo Polvikoski5, Mark Roberts6, Ana Töpf1, Kate Bushby1, Daniel McArthur7, Hanns Lochmüller1, Alessandra Ferlini2, Volker Straub1, Rita Barresi8.
Abstract
Dominant mutations in STIM1 are a cause of three allelic conditions: tubular aggregate myopathy, Stormorken syndrome (a complex phenotype including myopathy, hyposplenism, hypocalcaemia and bleeding diathesis), and a platelet dysfunction disorder, York platelet syndrome. Previous reports have suggested a genotype-phenotype correlation with mutations in the N-terminal EF-hand domain associated with tubular aggregate myopathy, and a common mutation at p.R304W in a coiled coil domain associated with Stormorken syndrome. In this study individuals with STIM1 variants were identified by exome sequencing or STIM1 direct sequencing, and assessed for neuromuscular, haematological and biochemical evidence of the allelic disorders of STIM1. STIM1 mutations were investigated by fibroblast calcium imaging and 3D modelling. Six individuals with STIM1 mutations, including two novel mutations (c.262A>G (p.S88G) and c.911G>A (p.R304Q)), were identified. Extra-neuromuscular symptoms including thrombocytopenia, platelet dysfunction, hypocalcaemia or hyposplenism were present in 5/6 patients with mutations in both the EF-hand and CC domains. 3/6 patients had psychiatric disorders, not previously reported in STIM1 disease. Review of published STIM1 patients (n = 49) confirmed that neuromuscular symptoms are present in most patients. We conclude that the phenotype associated with activating STIM1 mutations frequently includes extra-neuromuscular features such as hypocalcaemia, hypo-/asplenia and platelet dysfunction regardless of mutation domain.Entities:
Keywords: Exome sequencing; STIM1; Stormorken syndrome; Tubular aggregate myopathy; York platelet syndrome
Mesh:
Substances:
Year: 2017 PMID: 28624464 DOI: 10.1016/j.nmd.2017.05.002
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296